Eterna Therapeutics Files Q3 2024 10-Q

TL;DR

ETRN 10-Q filed: Q3 2024 financials out, check balance sheet details.

AI Summary

Eterna Therapeutics Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Brooklyn ImmunoTherapeutics, Inc., reported financial data for its fiscal quarters and year-to-date periods. Specific financial figures and balance sheet details for common stock, preferred stock, additional paid-in capital, and retained earnings as of June 30, 2024, and December 31, 2023, were included.

Why It Matters

This filing provides investors with an update on Eterna Therapeutics' financial health and performance for the third quarter of 2024, crucial for investment decisions.

Risk Assessment

Risk Level: medium — As a 10-Q filing, it contains detailed financial information that requires careful analysis to assess the company's financial health and future prospects, which can be complex.

Key Numbers

• 2024-09-30 — Reporting Period End Date (Indicates the end of the financial period covered by the report.)
• 2024-11-12 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
• 2023-12-31 — Previous Year End Date (Provides a comparison point for financial performance and position.)

Key Players & Entities

• Eterna Therapeutics Inc. (company) — Filer of the 10-Q
• Brooklyn ImmunoTherapeutics, Inc. (company) — Former name of Eterna Therapeutics Inc.
• 20240930 (date) — End of the reporting period
• 20241112 (date) — Filing date
• 0000748592 (company) — Central Index Key for Eterna Therapeutics Inc.

FAQ

Key Financial Figures

• $0.005 — nge on which registered Common stock, $0.005 par value per share ERNA The Nasdaq

Filing Documents

• form10-q.htm (10-Q) — 1081KB
• ex10-10.htm (EX-10.10) — 322KB
• ex10-11.htm (EX-10.11) — 22KB
• ex31-1.htm (EX-31.1) — 12KB
• ex31-2.htm (EX-31.2) — 12KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• form10-q_001.jpg (GRAPHIC) — 2KB
• 0001493152-24-044841.txt ( ) — 6567KB
• erna-20240930.xsd (EX-101.SCH) — 55KB
• erna-20240930_cal.xml (EX-101.CAL) — 69KB
• erna-20240930_def.xml (EX-101.DEF) — 244KB
• erna-20240930_lab.xml (EX-101.LAB) — 458KB
• erna-20240930_pre.xml (EX-101.PRE) — 378KB
• form10-q_htm.xml (XML) — 760KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Item 1.

Financial Statements (unaudited)

Financial Statements (unaudited) Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 1 Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023 2 Condensed Consolidated Statements of Changes in Stockholders' (Deficit) Equity for the three and nine months ended September 30, 2024 and 2023 3 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2024 and 2023 4 Notes to Condensed Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 23 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 32 Item 4.

Controls and Procedures

Controls and Procedures 33

– OTHER INFORMATION

PART II – OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 34 Item 1A.

Risk Factors

Risk Factors 34 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 34 Item 3. Defaults Upon Senior Securities 3 4 Item 4. Mine Safety Disclosures 34 Item 5. Other Information 34 Item 6. Exhibits 35

Signatures

Signatures 36 i CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 ("PSLRA"), Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements include plans, capital needs, and our financial position. Forward-looking statements are based on information currently available to us, on our current expectations, estimates, forecasts, and projections about the industries in which we operate and on the beliefs and assumptions of management. Forward looking statements often contain words such as "expects," "anticipates," "could," "targets," "projects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," "would," and similar expressions. In addition, any statements that refer to projections of our future financial performance, our anticipated growth and trends in our business, and other characterizations of future events or circumstances, are forward-looking statements. Forward-looking statements by their nature address matters that are, to different degrees, subject to risks and uncertainties that could cause actual results to differ materially and adversely from those expressed in any forward-looking statements. For us, particular factors that might cause or contribute to such differences include those risks and uncertainties described in Part I, Item 1A "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (the "SEC") on March 14, 2024, in Part II, Item 1A "Risk Factors" of this Quarterly Report on Form 10-Q, and in other documents we file from time to ti

View Full Filing

View this 10-Q filing on SEC EDGAR